Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura

Inclusion Criteria: * Age \>= 18 and \<= 65 years * ITP diagnosed at least 6 months prior to study entry by history, physical exam, blood count and blood smear * Baseline platelet count of \<= 20 x 10 to the 9th/L determined prior to administration of the study drug on the day of the first infusion * No IVIG treatment for ITP during the two weeks prior to the first infusion of the study drug * For females of child bearing potential, use of adequate birth control measures during study participation * Written informed consent Exclusion Criteria: * Serum values of ALT, AST, alkaline phosphatase, and total bilirubin exceeding 2.5 times the upper limit of normal at screening * Renal dysfunction defined as serum creatinine greater than or equal to 2 mg/dL at screening * Underlying other autoimmune or lymphoproliferative disorder * Uncontrolled hypertension * Cardiac insufficiency NYHA III and IV, coronary heart disease (CHD) NYHA III and IV * Malignancy or history of malignancy * Documented selective IgA deficiency (\<= 10 mg/dL) * Treatment with another investigational drug in the four weeks prior to study entry or current treatment with another investigational product * History of severe adverse reactions to blood and/or blood products * Pregnancy or lactation * Positivity for HIV, or HCV antibodies, or HBsAg * History of unresponsiveness to IVIG defined as a peak increment in platelet count \<= 20,000/µL coincident with the last IVIG treatment course prior to study entry